Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance
Galderma Group AG Registered Shares GALD
News
AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis
Skincare Specialist Galderma to Buy ZO Skin Health for $1.5 Billion — Update
Galderma to Buy ZO Skin Health for $1.5 Billion
Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering
New Galderma Research Reveals More Than Half of Women Mistake Menopause-Related Skin Changes for Signs of Ageing
Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older
30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis
EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies
Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing
Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.
/C O R R E C T I O N — Cetaphil/
Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping
Galderma Raises 2026 Sales Guidance on Strong Growth
Galderma Hits FDA Setback Again in Bid to Launch Botox Rival in U.S. — Update
Galderma Shares Fall After Bid to Launch Botox Rival in U.S. Hits FDA Setback
Galderma Application for Product to Rival Botox Turned Down Again by FDA
United States